



FINAL

**GYNECOLOGIC CANCER INTERGROUP (GCIG)
ENDOMETRIAL CANCER COMMITTEE
THURSDAY, JUNE 1, 2017, 1:00PM – 2:30PM
LASALLE I ROOM, DOUBLETREE HOTEL, CHICAGO
CHAIR: S.GREGGI CO-CHAIR: C.CREUTZBERG
HARMONIZATION LIAISONS: ADEMA/SAPETTO-REBOW (OPS); TU/EMBLETON (STATS)**

PLEASE SIGN ATTENDANCE FORMS

AGENDA

Welcome and Introductions and COI Disclosures (real or perceived) Creutzberg for Greggi

Approval of report/minutes: October 2016 (posted on GCIG website)

Motion: _____ **Seconded:** _____

CLOSED/PUBLISHED STUDIES Creutzberg for Greggi

- PORTEC-3 trial (DGOG)
- GOG-258 trial; GOG-249 (RTOG)
- TOTEM (MaNGO)

ONGOING TRIALS:

- FANDANGO [EN1] (NSGO) Mirza
- Chemotherapy versus Observation after surgery for N0 EC [EN2] (NSGO) Mirza
- PALEO [EN3] (NSGO) Mirza
- ECLAT (AGO) Harter
- NiCCC (SGCTC) Glasspool
- PORTEC-4a (DGOG) Creutzberg
- E.C.C.O. (MITO) Greggi

ACTIVATING TRIALS:

- STATEC (NCRI) McNeish
- TSR-042 [EN6] (NSGO) Mirza

NEW PROPOSALS/CONCEPTS:

- Multicenter retrospective study on the role of cytoreductive surgery in advanced endometrial carcinoma (MITO-AGO) Greggi-Mahner

CHALLENGING DEBATE:

First line chemotherapy versus molecular-genetics based treatment for recurrent or metastatic endometrial cancer

- Pro first line chemotherapy Fleming
- Pro molecular-based treatment Lu

Discussion and take home message

ADJOURN